期刊文献+

基于网络药理学探讨滋肾活络方改善高血压左室肥大的物质基础和作用机制

Material basis and mechanism of Zishenhuoluo Formula improving hypertension left ventricular hypertrophy based on network pharmacology
下载PDF
导出
摘要 目的基于网络药理学预测滋肾活络方改善高血压左室肥大的物质基础和作用机制。方法利用中药系统药理学数据库和分析平台(TCMSP)获取滋肾活络方所含化合物成分,筛选潜在活性成分;整合Swiss Target Prediction、The Human Phenotype Ontology(HPO)、DisGeNET数据库预测和筛选滋肾活络方改善高血压左室肥大作用靶点,以Cytoscape软件构建“单味药-活性成分-作用靶点”网络。STRING数据库进行靶点蛋白相互作用网络构建和分析,应用Ledock软件进行活性成分分子和关键靶点分子对接验证。采用Metascape数据库富集分析作用靶点涉及的功能及通路。结果滋肾活络方的38个活性成分作用于高血压左室肥大相关靶点47个,主要通过调控钙信号、肾上腺素能受体信号、5-羟色胺能突触、丝裂原活化蛋白激酶(MAPK)信号和过氧化物酶体增殖物激活受体(PPAR)信号通路等改善高血压左室肥大。结论滋肾活络方通过多个成分作用于多个靶点,多途径改善高血压左室肥大。 Objective To explore the material basis and mechanism of Zishenhuoluo formula(ZSHLF)improving hypertension left ventricular hypertrophy based on network pharmacology.Methods The chemical components of ZSHLF were obtained by using the TCMSP,and potential active components were screened.The Swiss Target Prediction,HPO,and DisGeNET databases were integrated to predict and screen the target of ZSHLF to improve hypertension myocardial hypertrophy.The STRING platform was used to construct and analyze the target protein interaction network,and the Ledock software was used to verify the docking of active ingredient molecules and key target molecules.Metascape database was used to enrich and analyze GO function and KEGG pathway involved in the target.Results The 38 active components of ZSHLF act on 47 targets related to hypertension-myocardial hypertrophy.ZSHLF may achieve its effects by regulating calcium signals,adrenergic receptor signals,serotoninergic synapses,MAPK signals and PPAR signaling pathways.Conclusions ZSHFL can improve hypertension-myocardial hypertrophy through multiple components acting on multiple targets,and provide scientific basis for in-depth study of its effectiveness basis and mechanism of action.
作者 吴智春 于华芸 宋晓彤 王媛 王华 王志宏 WU Zhi-Chun;YU Hua-Yun;SONG Xiao-Tong(Collgeg of Traditional Chinese Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250355,Shandong,China)
出处 《中国老年学杂志》 CAS 北大核心 2022年第1期5-11,共7页 Chinese Journal of Gerontology
基金 国家自然科学基金(81503539,82074135) 济南市高校自主培养创新团队(2020GXRC012)。
关键词 滋肾活络方 高血压左室肥大 网络药理学 活性药物成分 Zishenhuoluo Formula(ZSHLF) Hypertension left ventricular hypertrophy Network pharmacology Active pharmaceutical ingredient
  • 相关文献

参考文献7

二级参考文献50

  • 1卜培莉,侯晓阳,公茂磊,王淑贞,高莉,曹春林.血清胶原代谢指标在评价高血压左室重构中的作用[J].中华核医学杂志,2006,26(1):44-45. 被引量:1
  • 2Daniels A,van Bilsen M,Goldschmeding R,et al.Connective tissue growth factor and cardiac fibrosis.Acta physiologica (Oxford,England),2009,195:321-338.
  • 3Martos R,Baugh J,Ledwidge M,et al.Diastolic heart failure:evidence of increased myocardial collagen turnover linked to diastolic dysfunction.Circulation,2007,115:888-895.
  • 4Koitabashi N,Arai M,Kogure S,et al.Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis.Hypertension,2007,49:1120-1127.
  • 5Cucoranu I,Clempus R,Dikalova A,et al.NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts.Circ Res,2005,97:900-907.
  • 6Ago T,Sadoshima J.GDF15,a cardioprotective TGF-beta superfamily protein.Circ Res,2006,98:294-297.
  • 7Chen CN,Li YS,Yeh YT,et al.Synergistic roles of platelet-derived growth factor-BB and interleukin-1beta in phenotypic modulation of human aortic smooth muscle cells.PNAS,2006,103:2665-2670.
  • 8Thum T,Catalucci D,Bauersachs J.MicroRNAs:novel regulators in cardiac development and disease.Cardiovasc Res,2008,79:562-570.
  • 9van Rooij E,Sutherland LB,Thatcher JE,et al.Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.PNAS,2008,105:13027-13032.
  • 10Matkovich SJ,Wang W,Tu Y,et al.MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.Circ Res,2010,106:166-175.

共引文献107

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部